Drug Profile
Tipepidine - Taisho Pharmaceutical
Alternative Names: Tipepidine hibenzate; TS 141Latest Information Update: 15 Nov 2019
Price :
$50
*
At a glance
- Originator Unknown
- Developer Taisho Pharmaceutical
- Class Behavioural disorder therapies; Piperidines; Small molecules
- Mechanism of Action Inwardly rectifying potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 30 Oct 2019 Discontinued - Phase-II for Attention-deficit hyperactivity disorder (In adolescents, In children) in Japan (PO)
- 01 Oct 2019 TS 141 is still in phase II trials for Attention-deficit hyperactivity disorder in Japan (Taisho Pharmaceuticals website, September 2019)
- 15 Feb 2018 Taisho Pharmaceutical completes a phase II trial in Attention-deficit hyperactivity disorder (In children, In adolescents) in Japan (PO), before February 2018 (JapicCTI-163244)